Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance

Croatian Medical Journal

Volumn 47, Issue 3, 2006, Pages 410-415

  Su, Zhaoliang ^a   Xu, Huaxi ^a   Zhang, Chiyu ^a   Shao, Shihe ^a   Li, Liangju ^a   Wang, Hua ^a   Wang, Huifang ^a   Qiu, Gufeng ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; CLARITHROMYCIN; FURAZOLIDONE; METRONIDAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATION; DILUTION; ERADICATION THERAPY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; STOMACH BIOPSY; STOMACH DISEASE;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; FURAZOLIDONE; GASTRITIS; GENES, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 33745220769     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. van Amsterdam K, van Vliet AH, Kusters JG, van der Ende A. Of microbe and man: determinants of Helicobacter pylori-related diseases. FEMS Microbiol Rev. 2006;30:131-56.
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175-86.
3. Thomas JE, Dale A, Harding M, Coward WA, Cole TJ, Weaver LT. Helicobacter pylori colonization in early life. Pediatr Res. 1999;45:218-23.
4. Williamson JS. Helicobacter pylori: current chemotherapy and new targets for drug design. Curr Pharm Des. 2001;7:355-92.
5. McLoughlin RM, O'Morain CA, O'Connor HJ. Eradication of Helicobacter pylori: recent advances in treatment. Fundam Clin Pharmacol. 2005;19:421-7.
6. Leiros HK, Kozielski-Stuhrmann S, Kapp U, Terradot L, Leonard GA, McSweeney SM. Structural basis of 5-nitroimidazole antibiotic resistance: the crystal structure of NimA from Deinococcus radiodurans. J Biol Chem. 2004;279:55840-9.
7. Kim JG. Treatment of Helicobacter pylori infection [in Korean]. Korean J Gastroenterol. 2005;46:172-80.
8. Sisson G, Jeong JY, Goodwin A, Bryden L, Rossler N, Lim-Morrison S, et al. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori RdxA(+) (Nitroreductase) gene. J Bacteriol. 2000;182:5091-6.
9. Eisig JN, Silva FM, Rodriguez TN, Hashimoto CL, Barbuti RC. A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease. Clinics. 2005;60:485-8.
10. Kwon DH, Lee M, Kim JJ, Kim JG, El-Zaatari FA, Osato MS, et al. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother. 2001;45:306-8.
11. Guttner Y, Windsor HM, Viiala CH, Dusci L, Marshall BJ. Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study. Antimicrob Agents Chemother. 2003;47:3780-3.
12. Dai G, Cheng N, Dong L, Muramatsu M, Xiao S, Wang MW, et al. Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori. Antimicrob Agents Chemother. 2005;49:3468-73.
13. National Committee for Clinical Laboratory Standard. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A7. Wayne (PA): National Committee for Clinical Laboratory Standards; 2000.
14. Majewski SI, Goodwin CS. Restriction endonuclease analysis of the genome of Campylobacter pylori with a rapid extraction method: evidence for considerable variation. J Infect Dis. 1988;157:465-71.
15. Srinivasan V, Morowitz HJ. Ancient genes in contemporary persistent microbial pathogens. Biol Bull. 2006;210:1-9.
16. Wanken AE, Conway T, Eaton KA. The Entner-Doudoroff pathway has little effect on Helicobacter pylori colonization of mice. Infect Immun. 2003;71:2920-3.
17. Hughes NJ, Clayton CL, Chalk PA, Kelly DJ. Helicobacter pylori porCDAB and oorDABC genes encode distinct pyruvate: flavodoxin and 2-oxoglutarate: acceptor oxidoreductases which mediate electron transport to NADP. J Bacteriol. 1998;180:1119-28.
18. Nivinskas H, Koder RL, Anusevicius Z, Sarlauskas J, Miller AF, Cenas N. Quantitative structure-activity relationships in two-electron reduction of nitroaromatic compounds by Enterobacter cloacae NAD(P)H: nitroreductase. Arch Biochem Biophys. 2001;385:170-8.
19. Kwon DH, El-Zaatari FA, Kato M, Osato MS, Reddy R, Yamaoka Y, et al. Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob Agents Chemother. 2000;44:2133-42.
20. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med. 2003;139:463-9.
21. Shanyun, Xu Shuchang, Ye Yuankang. Analysis of Helicobacter pylori resistance rate [in Chinese]. Journal of Tongji University. 2004;25:31.
22. Liu Gaifang. Xu Huazhou, Zhang Yuzhen, Zhu Xuemei, Wu Jing. Resistance rate of Helicobacter pylori isolates [in Chinese]. Chinese Journal of Practical Internal Medicine. 2005;25:130.
23. Sisson G, Goodwin A, Raudonikiene A, Hughes NJ, Mukhopadhyay AK, Berg DE, et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother. 2002;46:2116-23.